{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:39:21Z","timestamp":1793623161588,"version":"4.5.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2016YFC1307003"],"award-info":[{"award-number":["2016YFC1307003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771446"],"award-info":[{"award-number":["81771446"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Obsessive-compulsive disorder (OCD) is a common chronic mental disorder with a high disability rate. Serotonin reuptake inhibitors (SRIs), including selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants, such as clomipramine, are the most common choices for the pharmacological treatment of OCD. Optimizing their use is pivotal in guiding clinical practice of OCD. However, there are few studies on the optimal dose of SRIs and there is controversy about their dose\u2013response relationship and optimal target dose. Therefore, the objective of this study was to summarize the relationship between the dose and effect of SRIs, as well as the optimal dose of SRIs for OCD, as to propose future research directions.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Medline, Embase, Biosis, PsycINFO, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, and CINAHL were searched for relevant publications, and the search was up to February 22, 2020. We used a one-stage, robust error meta-regression (REMR) model to deal with the correlated dose\u2013response data for SRIs from different studies. Doses of SRIs were converted to fluoxetine equivalents when performing dose\u2013response analysis. Review Manager Program Version 5.3 and STATA software package (version 15.1) were applied to analyze data. The study protocol was registered with PROSPERO (number CRD42020168344).<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Eleven studies involving 2,322 participants were included in final analysis. For SRIs, the dose\u2013efficacy curve showed a gradual increase trend in the 0\u201340-mg dose range and then had a decreased trend in doses up to 100 mg fluoxetine equivalent. Dropouts due to adverse effects gradually increased throughout the inspected dose slope. The curve of dose of all-cause dropouts suggested no relationship between them. Sensitivity analysis proved that these results were robust.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The systematic review found that the optimal dose for efficacy was about 40mg fluoxetine equivalent. Tolerability decreased with increased doses, and there was no significant correlation between acceptability and doses of SRIs. Therefore, the optimal dose of SRIs needs to consider effectiveness and tolerability.<\/jats:p><jats:p><jats:bold>Systematic Review Registration:<\/jats:bold> [PROSPERO], identifier [CRD42020168344].<\/jats:p>","DOI":"10.3389\/fpsyt.2021.717999","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T06:33:50Z","timestamp":1632378830000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Optimal Dose of Serotonin Reuptake Inhibitors for Obsessive-Compulsive Disorder in Adults: A Systematic Review and Dose\u2013Response Meta-Analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Jiao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinjian","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyi","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiguo","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"key":"B1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"B2","author":"Murray","year":"1996","journal-title":"The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020: Summary"},{"key":"B3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00127-010-0337-5","article-title":"Obsessive\u2013compulsive disorder in the community: 12-month prevalence, comorbidity and impairment","volume":"47","author":"Adam","year":"2011","journal-title":"Soc Psychiatry Psychiatr Epidemiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication","volume":"15","author":"Ruscio","year":"2008","journal-title":"Mol Psychiatry."},{"key":"B5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","article-title":"Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch Gen Psychiatry."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s00127-012-0507-8","article-title":"Obsessive\u2013compulsive disorder: prevalence, correlates, help-seeking and quality of life in a multiracial Asian population","volume":"47","author":"Subramaniam","year":"2012","journal-title":"Soc Psychiatry Psychiatr Epidemiol."},{"key":"B7","first-page":"5","article-title":"Practice guideline for the treatment of patients with obsessive-compulsive disorder","volume":"164","author":"Koran","year":"2007","journal-title":"Am J Psychiatry."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cpr.2004.08.004","article-title":"A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder","volume":"24","author":"Eddy","year":"2004","journal-title":"Clin Psychol Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"Cd001765","DOI":"10.1002\/14651858.CD001765.pub3","article-title":"Selective serotonin re-uptake inhibitors (SSRIs) vs. placebo for obsessive compulsive disorder (OCD)","volume":"2008","author":"Soomro","year":"2008","journal-title":"Cochrane Database Systemat Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1001\/archpsyc.1991.01810320054008","article-title":"Clomipramine in the treatment of patients with obsessive-compulsive disorder","volume":"48","author":"DeVeaugh-Geiss","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1176\/ajp.146.10.1328","article-title":"Obsessive-compulsive disorder: a double-blind, placebo-controlled trial of clomipramine in 27 patients","volume":"146","author":"Jenike","year":"1989","journal-title":"Am J Psychiatry."},{"key":"B12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1176\/appi.ajp.162.1.151","article-title":"Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder","volume":"162","author":"Foa","year":"2005","journal-title":"Am J Psychiatry."},{"key":"B13","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1192\/bjp.169.4.468","article-title":"Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators","volume":"169","author":"Zohar","year":"1996","journal-title":"Br J Psychiatry J Mental Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/jama.2017.2200","article-title":"Obsessive-compulsive disorder: advances in diagnosis and treatment","volume":"317","author":"Hirschtritt","year":"2017","journal-title":"J Am Med Assoc."},{"key":"B15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jpsychires.2021.02.060","article-title":"First manic\/hypomanic episode in obsessive-compulsive disorder patients treated with antidepressants: a systematic review","volume":"137","author":"Bertol\u00edn","year":"2021","journal-title":"J Psychiatr Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1017\/S1461145702002900","article-title":"Treatment non-response in OCD: methodological issues and operational definitions","volume":"5","author":"Pallanti","year":"2002","journal-title":"Int J Neuropsychopharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/mp.2009.50","article-title":"Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder","volume":"15","author":"Bloch","year":"2010","journal-title":"Mol Psychiatry."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.4088\/JCP.v64n0919","article-title":"Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine","volume":"64","author":"Hollander","year":"2003","journal-title":"J Clin Psychiatry."},{"key":"B19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00004850-200103000-00002","article-title":"Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder","volume":"16","author":"Montgomery","year":"2001","journal-title":"Int Clin Psychopharmacol."},{"key":"B20","first-page":"409","article-title":"Clinical usefulness of Fluvoxamine Maleate (SME3110), a selective serotonin reuptake inhibitor, in the treatment of obsessive compulsive disorder: a double blind, placebo-controlled study investigating the therapeutic dose range and the efficacy of SME3110","volume":"12","author":"Nakajima","year":"1996","journal-title":"J Clin Therapeut Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1001\/archpsyc.1994.03950070051010","article-title":"A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder","volume":"51","author":"Tollefson","year":"1994","journal-title":"Archiv Gen Psychiatry."},{"key":"B22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1001\/archpsyc.1995.03950160039008","article-title":"Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder","volume":"52","author":"Greist","year":"1995","journal-title":"Arch Gen Psychiatry."},{"key":"B23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0924-977X(93)90266-O","article-title":"A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group","volume":"3","author":"Montgomery","year":"1993","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"med PGJP. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e010919","DOI":"10.1136\/bmjopen-2015-010919","article-title":"Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis","volume":"6","author":"Furukawa","year":"2016","journal-title":"BMJ Open."},{"key":"B27","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/S2215-0366(19)30217-2","article-title":"Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis","volume":"6","author":"Furukawa","year":"2019","journal-title":"Lancet Psychiatry."},{"key":"B28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/9780470712184.ch10","article-title":"Addressing reporting biases","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series","author":"Sterne","year":"2008"},{"key":"B29","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.schres.2013.06.030","article-title":"How to compare doses of different antipsychotics: a systematic review of methods","volume":"149","author":"Patel","year":"2013","journal-title":"Schizophr Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/B978-0-08-018242-1.50015-5","article-title":"Dose equivalence of the antipsychotic drugs","author":"Davis","year":"1975","journal-title":"Catecholamines and Schizophrenia."},{"key":"B31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jad.2015.03.021","article-title":"Dose equivalents of antidepressants: evidence-based recommendations from randomized controlled trials","volume":"180","author":"Hayasaka","year":"2015","journal-title":"J Affect Disord."},{"key":"B32","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1192\/bjp.174.4.297","article-title":"Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials","volume":"174","author":"Bollini","year":"1999","journal-title":"Br J Psychiatry J Mental Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1176\/appi.ajp.2015.15030331","article-title":"Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder","volume":"173","author":"Jakubovski","year":"2016","journal-title":"Am J Psychiatry."},{"key":"B34","unstructured":"WHO Collaborative Centre for Drug Statistics Methodology. ATC\/DDD System2020"},{"key":"B35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/XEB.0000000000000132","article-title":"The robust error meta-regression method for dose-response meta-analysis","volume":"16","author":"Xu","year":"2018","journal-title":"Int J Evid Based Healthc."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jclinepi.2018.11.007","article-title":"The methodological quality of dose-response meta-analyses needed substantial improvement: a cross-sectional survey and proposed recommendations","volume":"107","author":"Xu","year":"2019","journal-title":"J Clin Epidemiol."},{"key":"B37","first-page":"1735","article-title":"Clomipramine for obsessive-compulsive disorder","volume":"43","author":"Feinberg","year":"1991","journal-title":"Am Fam Physician."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.717999\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T06:34:01Z","timestamp":1632378841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.717999\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":37,"alternative-id":["10.3389\/fpsyt.2021.717999"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.717999","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,23]]},"article-number":"717999"}}